Failed Induction (of Labor) by OxytocinPhase 4NCT02723461
Continuous Oxytocin Infusion Versus Pulsatile Intravenous Oxytocin for Augmentation of First Stage of Labor
A Phase 4 study testing Pulsatile Oxytocin and Continuous Oxytocin in people with Failed Induction (of Labor) by Oxytocin, run by Ain Shams Maternity Hospital at 1 site in Egypt.
Trial summary
Comparing continuous intravenous oxytocin infusion with pulsatile administration of intravenous oxytocin for augmentation of the first stage of labor. Read more about this study
- Who is it for?
- Ages 17 to 40 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Failed Induction (of Labor) by Oxytocin
- What is being tested?
- Pulsatile Oxytocin and Continuous Oxytocin
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 1 siteEgypt
- Study dates
- Mar 2016to Feb 2017
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 17 to 40 years
- Women only
- Healthy volunteers accepted
- Child, Adult
Who may be able to join
- Women in labor (cervical dilatation 3-4 centimeters) who require augmentation of first stage of labor.
- Single viable fetus.
- Rupture of membranes before augmentation of labor.
- Cephalic presentation.
- Term pregnancy.
Who cannot join
- Malpresentation.
- Induction of labor by prostaglandins.
- Any uterine previous surgery.
- Fetal anomalies.
- Premature labor.
- Previous cesarean section.
- Any uterine anomalies.
- Multiple pregnancy.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Randomised Controlled Trial Comparing Continuous Intravenous Oxytocin Infusion With Pulsatile Administration of Intravenous Oxytocin for Augmentation of the First Stage of Labor
Comparing continuous intravenous oxytocin infusion with pulsatile administration of intravenous oxytocin for augmentation of the first stage of labor.
Read the detailed description
The study population comprises120 cases with spontaneous onset of labor who are admitted to the labor ward at causalities of Ain shams university maternity hospital.
The required sample size has been calculated using the IBM© SamplePower© Software (IBM© Corp., Armonk, NY, USA). A previous study by Tribe et al., 2012 reported that the mean infusion to delivery time associated with continuous infusion of oxytocin was 7.17 hours with a 95% confidence interval (95% CI) of 6.58 to 7.77 hours versus 9.61 hours (95% CI, 8.95 to 10.27 hours) in association with pulsatile oxytocin. The sample size for either regimen in that study was 240 patients or 241 patients, respectively. From the study of Tribe et al. (2012), it could be estimated that the standard deviation (SD) for the infusion to delivery time was 4.66 hours or 5.23 hours for the continuous or pulsatile oxytocin regimen, respectively. This calculation is derived from solving any of the following equations for the SD given the mean, lower or upper 95% CI limit, and sample size:
Lower 95% CI limit = mean - (1.96 * SD / √n)..... Equation 1 Upper 95% CI limit = mean + (1.96 * SD / √n…..Equation 2 where SD is the standard deviation and n is the sample size (Chow et al., 2003).
So, it is estimated that a sample size of 66 patients in either study group (total, 132 patients) would achieve a power of 80% (type II error, 0.2) to detect a statistically significant difference between the two groups as regards the infusion to delivery time using a two-side unpaired Student t test with a confidence level of 95% (type I error, 0.05). the mean ± SD infusion to delivery time in both groups is assumed to be identical and to equal 9.61 ± 5.23 hours under the null hypothesis. Under the alternative hypothesis, the mean ± SD infusion to delivery time is assumed to equal 7.17 ± 4.66 hours in the continuous infusion group versus 9.61 ± 5.23 hours in the pulsatile group.
This sample size of 66 patients in each study group would have a power of 93% (type II error, 0.07) to detect a statistically significant difference between the two groups as regards the rate of successful induction of labor for a medium effect size (w) of 0.3 using a two-sided chi-squared test with a confidence level of 95% (type I error, 0.05). The effect size (w) is calculated as follows:
w =√(χ^2/N), where χ2 is the chi-squared statistic and N is the total sample size. (Chow et al., 2003).
Following admission, all patients will undergo complete clinical examination and detailed medical history will be obtained as follows:
- Personal history. B. Obstetric history: where the gestational age will be calculated by the date of last menstrual period or by ultrasonography in unreliable dates.
- Gynecological history.
Grouping:
The patients needing augmentation of first stage of labor will be divided equally into two groups:
Group 1 (study group ; 60 patients ) :
Patients at labor are given augmentation by oxytocin in pulsatile method
Group 2 (control group ;60 patients) :
Patients at labor are given augmentation by oxytocin in continuous method
Intervention:
Pulsatile group:
Pulsatile infusion protocol using a programmable syringe pump is applied .The pulsatile regime, oxytocin (Syntocinon,stock solution: 10 iU/mL) will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) will be doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes). This regime stems from the observation that physiologic oxytocin may be released in a pulsatile fashion every 4-6 minutes (Dawood et al.,1979)
Continuous group :
Continuous group will be administrated oxytocin (Syntocinon,stock solution: 10 iU/mL) at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10minutes).
Then each patient will have case record form in which the following data will be recorded:
- Patient initials.
- Study number.
- Group.
- Parity.
- Gestatinal age ( first day of last menstrual period - early ultrasound).
- Rupture of membranes.
- Duration of rupture of membranes.
- Duration of first stage of labour.
- Duration of second stage of labour.
- Need for instrumental delivery.
- Need for Cesarean section.
- Adverse effect.
- Neonatal outcome.
- Maternal complications.
- Adverse effect related to oxytocin.
- Total dose of oxytocin infused.
- Previous complicated vaginal delivery.
- Conditions
- Failed Induction (of Labor) by Oxytocin
- Being tested
- Pulsatile Oxytocin, Continuous Oxytocin
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pulsatile OxytocinDrug
Also called syntocinon
Using a programmable syringe pump, oxytocin will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
Continuous OxytocinDrug
Also called syntocinon
Oxytocin will be administered at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
| Study group | Role | What they receive |
|---|---|---|
| pulsatile oxytocin | Active comparator | Using a programmable syringe pump, the pulsatile regime, oxytocin (Syntocinon, stock solution: 10 iU/mL) will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes). This regime stems from the observation that physiologic oxytocin may be released in a pulsatile fashion every 4-6 minutes (Dawood et al.,1979) Receives: Drug: Pulsatile Oxytocin |
| continuous oxytocin | Active comparator | Continuous group will be administrated oxytocin (Syntocinon, stock solution: 10 iU/mL) at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes). Receives: Drug: Continuous Oxytocin |
What is being measured
The primary outcome is the main question the study is designed to answer.
duration of active phase of first stage of labor
The time in hours from start of infusion of pulsatile oxytocin at onset of established labor (cervical dilatation 3-4 cm ) to the end of first stage of labour (cervical dilatation 10 cm)
Measured: 24 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Mar 2016 (estimated)
- Study startMar 2016
- Primary completionJan 2017 (estimated)
- Study completionFeb 2017 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Failed Induction (of Labor) by OxytocinStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ain Shams Maternity Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Amr Ahmed Mahmoud Riad, Ain Shams Maternity Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02723461
- Sponsor's protocol ID
- pulsatile oxytocin
- Status last verified
- Sep 2016
- First submitted
- 26 Mar 2016
- Last updated
- 20 Sep 2016
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 20 Sep 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomised Controlled Trial Comparing Continuous Intravenous Oxytocin Infusion With Pulsatile Administration of Intravenous Oxytocin for Augmentation of the First Stage of Labor
- ClinicalTrials.gov ID
- NCT02723461
- Acronym / sponsor ID
- pulsatile oxytocin
- Conditions
- Failed Induction (of Labor) by Oxytocin
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Ain Shams Maternity HospitalUniversity, hospital or other
- Study start
- Mar 2016
- Primary completion
- Jan 2017 (estimated)
- Study completion
- Feb 2017 (estimated)
- First posted
- 30 Mar 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Comparing continuous intravenous oxytocin infusion with pulsatile administration of intravenous oxytocin for augmentation of the first stage of labor.
Detailed description
The study population comprises120 cases with spontaneous onset of labor who are admitted to the labor ward at causalities of Ain shams university maternity hospital.
The required sample size has been calculated using the IBM© SamplePower© Software (IBM© Corp., Armonk, NY, USA). A previous study by Tribe et al., 2012 reported that the mean infusion to delivery time associated with continuous infusion of oxytocin was 7.17 hours with a 95% confidence interval (95% CI) of 6.58 to 7.77 hours versus 9.61 hours (95% CI, 8.95 to 10.27 hours) in association with pulsatile oxytocin. The sample size for either regimen in that study was 240 patients or 241 patients, respectively. From the study of Tribe et al. (2012), it could be estimated that the standard deviation (SD) for the infusion to delivery time was 4.66 hours or 5.23 hours for the continuous or pulsatile oxytocin regimen, respectively. This calculation is derived from solving any of the following equations for the SD given the mean, lower or upper 95% CI limit, and sample size:
Lower 95% CI limit = mean - (1.96 * SD / √n)..... Equation 1 Upper 95% CI limit = mean + (1.96 * SD / √n…..Equation 2 where SD is the standard deviation and n is the sample size (Chow et al., 2003).
So, it is estimated that a sample size of 66 patients in either study group (total, 132 patients) would achieve a power of 80% (type II error, 0.2) to detect a statistically significant difference between the two groups as regards the infusion to delivery time using a two-side unpaired Student t test with a confidence level of 95% (type I error, 0.05). the mean ± SD infusion to delivery time in both groups is assumed to be identical and to equal 9.61 ± 5.23 hours under the null hypothesis. Under the alternative hypothesis, the mean ± SD infusion to delivery time is assumed to equal 7.17 ± 4.66 hours in the continuous infusion group versus 9.61 ± 5.23 hours in the pulsatile group.
This sample size of 66 patients in each study group would have a power of 93% (type II error, 0.07) to detect a statistically significant difference between the two groups as regards the rate of successful induction of labor for a medium effect size (w) of 0.3 using a two-sided chi-squared test with a confidence level of 95% (type I error, 0.05). The effect size (w) is calculated as follows:
w =√(χ^2/N), where χ2 is the chi-squared statistic and N is the total sample size. (Chow et al., 2003).
Following admission, all patients will undergo complete clinical examination and detailed medical history will be obtained as follows:
- Personal history. B. Obstetric history: where the gestational age will be calculated by the date of last menstrual period or by ultrasonography in unreliable dates.
- Gynecological history.
Grouping:
The patients needing augmentation of first stage of labor will be divided equally into two groups:
Group 1 (study group ; 60 patients ) :
Patients at labor are given augmentation by oxytocin in pulsatile method
Group 2 (control group ;60 patients) :
Patients at labor are given augmentation by oxytocin in continuous method
Intervention:
Pulsatile group:
Pulsatile infusion protocol using a programmable syringe pump is applied .The pulsatile regime, oxytocin (Syntocinon,stock solution: 10 iU/mL) will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) will be doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes). This regime stems from the observation that physiologic oxytocin may be released in a pulsatile fashion every 4-6 minutes (Dawood et al.,1979)
Continuous group :
Continuous group will be administrated oxytocin (Syntocinon,stock solution: 10 iU/mL) at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10minutes).
Then each patient will have case record form in which the following data will be recorded:
- Patient initials.
- Study number.
- Group.
- Parity.
- Gestatinal age ( first day of last menstrual period - early ultrasound).
- Rupture of membranes.
- Duration of rupture of membranes.
- Duration of first stage of labour.
- Duration of second stage of labour.
- Need for instrumental delivery.
- Need for Cesarean section.
- Adverse effect.
- Neonatal outcome.
- Maternal complications.
- Adverse effect related to oxytocin.
- Total dose of oxytocin infused.
- Previous complicated vaginal delivery.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| pulsatile oxytocin | Active comparator | Drug: Pulsatile OxytocinUsing a programmable syringe pump, the pulsatile regime, oxytocin (Syntocinon, stock solution: 10 iU/mL) will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes). This regime stems from the observation that physiologic oxytocin may be released in a pulsatile fashion every 4-6 minutes (Dawood et al.,1979) |
| continuous oxytocin | Active comparator | Drug: Continuous OxytocinContinuous group will be administrated oxytocin (Syntocinon, stock solution: 10 iU/mL) at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes). |
Who may qualify
- Ages
- 17 to 40 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
Key inclusion criteria (5 listed)
- Women in labor (cervical dilatation 3-4 centimeters) who require augmentation of first stage of labor.
- Single viable fetus.
- Rupture of membranes before augmentation of labor.
- Cephalic presentation.
- Term pregnancy.
Key exclusion criteria (8 listed)
- Malpresentation.
- Induction of labor by prostaglandins.
- Any uterine previous surgery.
- Fetal anomalies.
- Premature labor.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pulsatile OxytocinAlso: syntocinonUsing a programmable syringe pump, oxytocin will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes). | Drug | pulsatile oxytocin |
| Continuous OxytocinAlso: syntocinonOxytocin will be administered at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes). | Drug | continuous oxytocin |
Primary outcome
duration of active phase of first stage of labor
Time frame: 24 hours
The time in hours from start of infusion of pulsatile oxytocin at onset of established labor (cervical dilatation 3-4 cm ) to the end of first stage of labour (cervical dilatation 10 cm)
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Sep 2016.
- Individual participant dataSharing planned: Undecided
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Pulsatile Oxytocin and Continuous Oxytocin in people with Failed Induction (of Labor) by Oxytocin, run by Ain Shams Maternity Hospital at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 20 Sep 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Amr A Riad, MD (01005347179 ext. +2, amr.riad@med.asu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
duration of active phase of first stage of labor (time frame: 24 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Sep 2016.